Two Sigma Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History

Two Sigma Advisers’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-196,076	Closed	-$267K	–	196
2025 Q4	$267K	Sell	196,076 -300	-0.2%	-$438	﹤0.01%	2019
2025 Q3	$314K	Buy	+196,376	New	+$320K	﹤0.01%	1969
2023 Q3	–	Sell	-84,952	Closed	-$630K	–	2384
2023 Q2	$630K	Sell	84,952 -48,964	-37%	-$417K	﹤0.01%	1726
2023 Q1	$1.27M	Sell	133,916 -105,400	-44%	-$1.11M	﹤0.01%	1511
2022 Q4	$2.55M	Buy	239,316 +195,100	+441%	+$1.98M	0.01%	1109
2022 Q3	$326K	Buy	44,216 +18,800	+74%	+$117K	﹤0.01%	2012
2022 Q2	$122K	Buy	+25,416	New	+$144K	﹤0.01%	2365
2021 Q1	–	Sell	-10,000	Closed	-$78K	–	2547
2020 Q4	$78K	Buy	+10,000	New	+$109K	﹤0.01%	2289

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's ATNM Position: Q1 2026 in Review

Two Sigma Advisers sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 196,076 shares — an estimated $267K sold.

Two Sigma Advisers first reported a position in ATNM in Q4 2020 and held it in 8 quarters. The position peaked at $2.55M in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Two Sigma Advisers reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 196,076 Actinium Pharmaceuticals shares in Q1 2026, an estimated $267K.
Two Sigma Advisers first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Two Sigma Advisers's Actinium Pharmaceuticals position peaked at $2.55M in Q4 2022.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.